Application of ATR/Chk1 signal channel inhibitor in promoting erythrocyte denucleation

• Main Authors: YIN JIAYING, LYU XIANG
• Format: Patent
• Language: Chinese; English
• Published: 04.04.2025
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The invention provides application of an ATR/Chk1 signal channel inhibitor in promoting erythrocyte denucleation, and experiments prove that the ATR/Chk1 signal channel inhibitor can promote denucleation of an erythroid in-vitro differentiation system derived from fetal liver and an erythroid in-vitro differentiation system derived from peripheral blood and promote denucleation of erythroblasts in bone marrow. The ATR/Chk1 signaling pathway inhibitor can also promote erythrocyte denucleation in bone marrow and spleen of a thalassemia subject, and has a good application prospect in treatment of erythrocyte denucleation abnormality related diseases. 本发明提供了ATR/Chk1信号通路抑制剂在促进红细胞脱核中的应用，并通过实验证明ATR/Chk1信号通路抑制剂能促进胎肝来源的红系体外分化体系和外周血来源的红系体外分化体系脱核、促进骨髓内成红细胞脱核，ATR/Chk1信号通路抑制剂还能促进地中海贫血受试者骨髓内、脾脏内成红细胞脱核，在治疗红细胞脱核异常相关疾病中有良好的应用前景。